Biocardia reports first quarter 2022 business highlights and financial results

Sunnyvale, calif., may 11, 2022 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2022 and filed its quarterly report on form 10-q for the three months ended march 31, 2022 with the securities and exchange commission. the company will also hold an update conference call today at 4:30 pm et. following management's formal remarks, there will be a question-and-answer session.
BCDA Ratings Summary
BCDA Quant Ranking